Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Citius Oncology, Inc.NASDAQ: CTOR

Other Income / Expenses · Q2 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q2 FY2026 other income / expenses was $1.77M, compared with $0 a year earlier. Trailing-twelve-month other income / expenses was $1.57M.

Context

  • Other income / expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $1.77M or moves back toward the trailing-twelve-month quarterly average of $393.37K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.77M+10199.1% QoQ
Last fiscal yearSep 2025
-$181.66K— YoY
LTMMar 2026
$1.57M— YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(181.66K) USD
Year-over-year change
—

Other Income / Expenses vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 other income / expenses of $1.57M is the 6th highest of the 10 companies compared; the peer median is $1.99M.
  • Other income / expenses amounts to 28.0% of revenue for CTOR, versus a peer median of 115.2%.
CTOR Competitors Peer median
Other Income / Expenses for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LNSRLENSAR, Inc.LTM Mar 2026$45.95M +197.9%—79.6%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$40.74M -24.4%—3552.1%
FATEFate Therapeutics, Inc.LTM Mar 2026$9.52M -61.3%-24.7%150.7%
FBRXForte Biosciences, Inc.LTM Mar 2026$2.53M +109.2%+414.8%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.99M -54.2%—3.6%
CTORCitius Oncology, Inc.LTM Mar 2026$1.57M ——28.0%
ACTUActuate Therapeutics IncLTM Mar 2026$299.11K +119.3%+78.0%—
OWLTOwlet, Inc.LTM Mar 2026-$34.98M -816.0%—32.7%
SCLXScilex Holding CompanyLTM Mar 2026-$116.93M -775.7%—345.3%
VORVor Biopharma Inc.LTM Mar 2026-$509.57M -14437.9%——
Peer median (excluding CTOR) $1.99M-54.2%+78.0%115.2%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.